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LETTERS TO THE EDITORRELATION BETWEEN
HEMODYNAMIC BEHAVIOR
AND OCCURRENCE OF EARLY
STENOTIC FAILURE OF
BIOPROSTHESES
To the Editor:
In the May issue of the Journal,
Jamieson and Fradet1 comment on
a recent Brief Communication by Law-
ton and colleagues2 in which 4 cases of
early failure of the Mosaic (Medtronic
Inc, Minneapolis, Minn) porcine
bioprosthesis are described, with devel-
opment of severe valve stenosis neces-
sitating replacement. In their letter,
Jamieson and Fradet question the diag-
nosis of early structural valve degener-
ation (SVD) in these explants, stating
that the valves reported by Lawton
and colleagues were either thrombosed
or covered by pannus.
We recently performed long-term
clinical and echocardiographic follow-
up in a series of 564 aortic bioprostheses
(among which 152 were Mosaic valves)
with the emphasis on studying the
occurrence of structural valve deteriora-
tion as determined by echocardiogra-
phy.3 We demonstrated a link between
the presence of prosthesis–patient mis-
match (PPM) defined as an indexed ef-
fective orifice area (EOAi, cm2/m2)
less than 0.85 and the occurrence of
early, stenotic-type SVD3 with elevated
transvalvular gradients. We showed that
patients with PPM are at risk for
stenotic-type SVD, starting to occur
from 3 to 4 years after implantation. In
Lawton and colleagues’2 study, 3 of
the 4 cases presented had an EOAi lessThe Editor welcomes submissions for possible publica-
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1200 The Journal of Thoracic andthan 0.85 and therefore had moderate
PPM. The remaining patient had an
EOAi of 0.89, which is borderline. The
observed early dysfunction in these
valves cannot be ignored, given the
reported transvalvular gradients and ef-
fective orifice areas before their explan-
tation.2 Lawton and colleagues have
made a correct observation of 4 early,
stenotic-type valve failures in patients
with moderate PPM. It might still be
that both pannus and thrombus were
present in these valves, and that these el-
ements were (partially) responsible for
the pathologic hemodynamic behavior.
But what causes such an early extensive
pannus formation or early thrombotic
changes at the surface of an aortic
bioprosthesis? As stated by Carpentier4
in his editorial on our article, a relation
between disturbed or turbulent trans-
valvular flow (as is the case when PPM
is present) and bioprosthetic tissue fail-
ure has been suspected before but was
never demonstrated. Banbury and col-
leagues5 noted a tendency for smaller bi-
oprostheses to fail earlier, but they did
not observe statistical significance in
their analysis.
In our series, none of the implanted
Mosaic valves has been explanted yet,
but 7 of the 152 Mosaic valves have
met our (echocardiography-based) cri-
teria for stenotic-type SVD on follow-
up echocardiography. The earliest was
already observed after 2.5 years after
implantation. Six of these patients
had moderate PPM (EOAi range
0.66–0.82), and the remaining patient
had an EOA index of 0.88. PPM might
not be harmful for the patient, but for
the valve..
Bart Meuris, MD, PhD
Willem Flameng, MD, PhD
Department of Cardiovascular
Diseases
Katholieke Universiteit Leuven
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This communication is in re-
sponse to the Letter to the Editor by
Meuris and Flameng1 in response to
our Letter to the Editor2 commenting
on the brief communication by Lawton
and colleagues.3 We identified that
Lawton and colleagues misrepresented
thrombosis and pannus (nonstructural
dysfunction) as durability issues.
Meuris and Flameng1 are challenging
our judgment and stating that Lawton
and colleagues3 ‘‘have made a correct
observation of four early, stenotic-type
valve failures in patients with moderate
PPM.’’ We also stated ‘‘the radiographs
were reported as part of the pathological
reports, showing no mineralization of
valve tissue in three and remnants of
mineralization of host tissue on the sew-
ing ring of the other prosthesis.’’ We
have reviewed all the documentation, in-
cluding the radiographs, and stand with
our original report.
Meuris and Flameng’s concern is re-
lated to evidence recently published by
Flameng and colleagues.1,4 These
investigators evaluated the relationship
of structural valve degeneration (SVD)
and prosthesis–patient mismatch
(PPM) (indexed effective orifice area
[EOAi] to body surface area with
known referenced effective orifice areas
by prosthesis size). They found no rela-
tionship to survival for the level of
EOAi, the same lack of influence as
we found,5 but PPM less than 0.85
cm2/m2 is predictive of SVD (hazard10
TABLE 1. Survey of United Kingdom
consultant practice
Regimen
Percent of
respondents
Warfarin 3 mo 15%
Warfarin>3 mo 0%
Aspirin 3 mo 10%
Aspirin>3 mo 48%
No medication 10%
Other regimens 17%
Letters to the Editorratio, 2.54; P ¼ .006). Stenosis-type
SVD developed early (3–4 years) in pa-
tients with PPM, whereas incompetent-
type SVD developed late (up to 9 years)
in patients without PPM. These authors
hypothesized a causative relationship of
SVD to PPM.
This report by Flameng and col-
leagues4 is the first to suggest a relation-
ship of SVD to PPM (EOAi<0.85 cm2/
m2). The other independent risk factor
for early stenotic-type SVD was valve
size of 21 mm or less. Valve size had
no relationship to incompetent-type
late SVD. Of the 564 patients, 152 had
Medtronic Mosaic (Medtronic Inc,
Minneapolis, MN) implants, and cur-
rently Flameng and colleagues4 have 7
patients being followed for early
stenosis-type SVD. Flameng and col-
leagues4 conclude by stating ‘‘by avoid-
ing PPM, the incidence of SVD should
be reduced by 50%.’’
We propose an alternative relation-
ship that SVD developing in smaller
size valve with reduced EOA may be
identified earlier because of PPM
advancing over time. The same hypoth-
esis could be related to late incompetent-
type SVD with degenerated changes not
developing stenosis in larger valves, and
consequently the development of leaflet
tears and incompetence from late SVD
causing problems of stress-related dis-
ease. In our reported study on AVR
PPM, survival was not influenced by
level of PPM, but bioprostheses was
a predictive factor.5
The challenge to us that Lawton
and colleagues’3 experience is SVD
caused by moderate PPM is not accept-
able, and further investigation is re-
quired. These valves had no
documented bioprosthetic tissue degen-
erative changes and no mineralization
of leaflet tissue on explant radiographs.
In our experience, thrombosis devel-
oped in a small percentage of Medtronic
Mosaic prostheses, possibly because of
the abnormal coagulation profile.
We do not agree with Meuris and
Flameng1 that Lawton and col-
leagues3 made the correct conclusion.
We think our observations are correct,The Journaland these valves do not have SVD de-
veloping early from moderate PPM
(in fact, we consider moderate PPM
an EOAi of> 0.65–0.75 cm2/m2; 1
of the cases should be classified as
mild PPM, 2 cases should be classi-
fied just mild at 0.83 cm2/m2, and 1
case should be classified with no
PPM at the time of implantation).
We agree with Meuris and Flameng1
that this phenomenon requires further
extensive investigation.
W. R. Eric Jamieson, MD
Guy J. Fradet, MD
Department of Surgery
University of British Columbia
Vancouver, British Columbia, CanadaReferences
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BIOPROSTHETIC AORTIC
VALVE REPLACEMENT
To the Editor:
We read with interest the article by
ElBardissi and colleagues.1 We concur
with their conclusions that early anti-
coagulation after isolated biopros-
thetic aortic valve replacement in
patients in sinus rhythm does not
seem to reduce the risks of thrombo-
embolism, except in high-risk groups,
and that current recommendations
should be revisited.of Thoracic and Cardiovascular SurgerIn a review of this subject, we2
learned that data are not uniform owing
to the retrospective analysis of the ma-
jority of the articles. Only 2 are prospec-
tive randomized trials comparing an
antiplatelet agent with vitamin K antag-
onist3,4 and unclear anticoagulation and
antithrombotic regimens. Furthermore,
in many of the studies, the results of aor-
tic and mitral valve replacements are
combined. Despite this lack of evi-
dence, guidelines for management of
patients with valvular heart disease pub-
lished by American College of Cardiol-
ogy, American Heart Association,
American College of Chest Physicians,
and European Society of Cardiology all
recommend the use of an anticoagula-
tion regimen for the first 3 months after
bioprosthetic aortic valve replacement.
ElBardissi and colleagues1 have
pointed out that practice differs widely
from these recommendations. We
carried out a survey of 194 United King-
dom consultant cardiac surgeons on an-
tithrombotic therapy after bioprosthetic
aortic valve replacement and received
171 (88%) responses (Table 1). Be-
cause of the diverse results of this sur-
vey and insufficient evidence in the
literature, like ElBardissi and col-
leagues, we believe that a randomized
trial would be necessary.
We embarked on a feasibility phase
of this trial. If a definitive randomized
trial comparing aspirin with warfarin
sodium monotherapy is considered, as-
suming a stroke rate of 1% to 5% per
person-year, 1800 patients are required
in each group. If a 3-armed trial com-
paring aspirin with warfarin or with
no therapy is considered, approxi-
mately 5400 patients are required iny c Volume 140, Number 5 1201
